What to expect in the GRAIL, Inc. interview process

Based on publicly available sources, GRAIL, Inc. is a Menlo Park, California-headquartered biotechnology and healthcare services company specializing in blood-based early cancer detection technologies, multi-cancer early detection, and precision oncology. Founded in 2015 and publicly traded on the NASDAQ (GRAL), the company operates across six countries, including the United States, United Kingdom, Philippines, Sweden, and Malta, with additional domestic locations in Washington, D.C., North Carolina, and the UK.

Publicly available workforce intelligence data indicates that GRAIL employed roughly 929 to 1,027 people globally as of March 2026, reflecting a headcount decline of roughly 26% to 26.5% compared to 2023 figures. Despite this multi-year contraction, hiring signals show a rebound: active job postings increased by 61.4% in 2026 compared to the previous year, with 66 active openings recorded.

Employer branding highlights a multi-disciplinary environment composed of scientists, engineers, clinicians, operators, and commercial teams working on next-generation sequencing, population-scale clinical studies, and data science. The company was recognized on the Built In 2026 Best Places to Work list. However, external business analyses note that GRAIL operates amid notable market headwinds, having navigated recent legal challenges and investor lawsuits while scaling its commercial diagnostics and research offerings.